Skip to main content
. 2017 Oct 26;8(6):1297–1308. doi: 10.1007/s13300-017-0324-x

Table 3.

Predictors of HbA1c reduction after 36 months of liraglutide treatment

Linear regression analysis Model Standardized coefficients Significance
Beta t
1 (Variable)
 (Constant) 1.760 0.089
 Duration of DM 0.064 0.594 0.557
 BMI before liraglutide introduction − 0.314 − 3.188 0.004*
 ALT before liraglutide treatment − 0.034 − 0.238 0.813
 AST before liraglutide treatment − 0.243 − 1.737 0.093
 HbA1c before liraglutide introduction − 0.790 − 5.762 0.000*
 FBG before liraglutide treatment − 0.135 − 0.935 0.358
 PPG before liraglutide treatment 0.104 0.792 0.435
 C-peptide level before liraglutide treatment 0.182 1.704 0.100
 Systolic blood pressure before liraglutide treatment 0.305 2.893 0.007*
 Diastolic blood pressure before liraglutide treatment − 0.087 − 0.879 0.387
 Cholesterol level before liraglutide treatment 0.610 2.463 0.020*
 HDL before liraglutide treatment − 0.039 − 0.314 0.756
 LDL before liraglutide treatment − 0.431 − 1.919 0.065
 Triglyceride level before liraglutide treatment 0.043 0.379 0.707
 TSH before liraglutide treatment 0.017 0.172 0.865
 Age of the patient 0.031 0.310 0.759

Linear regression analysis model; * p < 0.05

FBG fasting blood glucose, PPG postprandial blood glucose, TSH thyroid stimulating hormone